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Objective: To study the effects of Shuxuetong injection in adjuvant treatment of
ischemic stroke on the degree of nerve injury, lipid metabolism and blood coagulation
function.
Methods: Patients with ischemic stroke admitted in our hospital during the period from
May 2012 to May 2015 were selected for retrospective analysis. They were divided into
the control group receiving regular treatment and the Shuxuetong group receiving
adjuvant treatment with Shuxuetong injection. One and the three months after treatment,
serum was collected and nerve injury molecules, indexes of lipid metabolism and blood
coagulation function were measured.
Results: One month after treatment, the contents of neuron-speciﬁc enolase, S100 cal-
cium binding protein B, total cholesterol, triglyceride, low-density lipoprotein, oxidized
low-density lipoprotein, thromboxane B2, ﬁbrinogen and D-dimer in the serum of patients
from Shuxuetong group were signiﬁcantly lower than those of control group. The con-
tents of high-density lipoprotein and 6-keto prostaglandin F1a were signiﬁcantly higher
than those of control group. Three months after treatment, the contents of neuron-speciﬁc
enolase, S100 calcium binding protein B, total cholesterol, triglyceride, low-density li-
poprotein, oxidized low-density lipoprotein, thromboxane B2, ﬁbrinogen and D-dimer in
the serum of patients from Shuxuetong group were signiﬁcantly lower than those of
control group. The contents of high-density lipoprotein and 6-keto prostaglandin F1a were
signiﬁcantly higher than those of control group.
Conclusions: Adjuvant treatment with Shuxuetong injection can reduce the injury of
nerve function of patients with ischemic stroke and improve blood lipid metabolism and
blood coagulation function, which is an effective drug for the treatment of ischemic
stroke.1. Introduction
Ischemic stroke is a common disease in neurology with high
disability rate andmortality rate, bringing great burden to the family
and society. Atherosclerosis is a pathological basis of ischemic
stroke, and local thrombosis will lead to interruption of blood ﬂow
andcerebralhypoxic-ischemicdamage[1,2].Due to thepoor tolerance
of nerve cells to ischemia and hypoxia, cerebral infarction within a
short time will cause irreversible damage. Although thrombolysis,intervention and other treatment methods are able to make the
brain tissue get blood reperfusion, the patients will still have
neurological dysfunction in various degrees. Besides, there is a big
risk of relapse of cerebral infarction in the recovery process of
neurological function for patients with ischemic stroke, which will
further increase the injury of nerve function[3,4].
It is recognized that the abnormal lipid metabolism and
coagulation function are closely related to the occurrence and
development of atherosclerosis. Correcting lipid metabolism and
abnormal blood coagulation is the key measure to treat ischemic
stroke, which can not only improve the recovery of nerve
function, but also reduce the risk of stroke recurrence. Lipid-
lowering drugs and anticoagulant drugs commonly used in
western medicine include atorvastatin, aspirin and clopidogrel,
which belong to conventional drugs for the secondary preven-
tion of ischemic stroke with the exact lipid-lowering andBY-NC-ND license (http://
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stroke, the situation of lipid metabolism and abnormal
coagulation function in vivo is more serious, and the effect is
not ideal depending only on western medicine. Shuxuetong
injection is a traditional Chinese medicine with the effect of
promoting blood circulation to remove blood stasis and can
regulate lipid metabolism and blood coagulation function. In
the following study, the clinical effects of Shuxuetong
injection in adjuvant treatment of ischemic stroke were analyzed.Table 1
The clinical data of the two groups.
Parameters Shuxuetong
group (n = 35)
Control
group (n = 39)
Sex (male/female) 22/13 25/14
Age (years) 58.10 ± 7.20 57.40 ± 8.30
BMI (kg/m2) 23.89 ± 3.24 23.61 ± 3.09
High blood
pressure [n (%)]
19 (54.29) 22 (56.41)
Diabetes [n (%)] 13 (37.14) 15 (38.46)
Smoking [n (%)] 23 (65.71) 24 (61.54)2. Materials and methods
2.1. Research objects
Patients with ischemic stroke treated in our hospital during the
period from May 2012 to May 2015 were enrolled in the research.
All the patients were in line with the diagnostic criteria of cerebral
infarction according to Internal Medicine (8th edition)[8] and the
diagnostic criteria of stroke according to Standards of Syndrome-
Differentiated Diagnosis of Stroke[9], admitted to the hospital
within 72 h after onset and having complete medical records. The
following cases were excluded: patients complicated with cerebral
tumor and cerebral trauma, cerebral hemorrhage and heart, liver
and kidney insufﬁciency. A total of 74 patients were enrolled in
the two groups of Shuxuetong group and control group according
to the different treatment regimens after the medical records were
analyzed retrospectively.
2.2. Therapeutic methods
Patients of the two groups were given conventional symp-
tomatic and supportive treatment, including the maintenance of
water and electrolyte balance, nerve nutrition, improvement of
encephaledema and antibiotic resistance to infection, mean-
while, given 100 mg aspirin enteric-coated tablets (p.o., one time
a day), 75 mg sulfate clopidogrel tablets (p.o., one time a day),
20 mg atorvastatin (p.o., one time a day) and 30 mg edaravone
injection with 250 mL normal saline (i.v., one time a day). On
the basis of above regular treatments, patients of Shuxuetong
group were given Shuxuetong injection treatment. The method
was as follow: 8 mL Shuxuetong injection with 250 mL normal
saline (i.v., one time a day).
2.3. Neurologic evaluation assay
One month and three months after the treatment, the pe-
ripheral blood samples (5 mL) of the two groups were collected.
After obtaining serum by centrifugation, the contents of S100
calcium binding protein B (S100B) and neuron-speciﬁc enolase
(NSE) were determined by ELISA kit.
2.4. Lipid metabolism and blood coagulation indexes
One month and three months after the treatment, serum
samples used in the neural damage evaluation assay were used to
detect the contents of triglyceride (TG), total cholesterol (TC),
low density lipoprotein (LDL), high density lipoprotein (HDL),
oxidized low-density lipoprotein (ox-LDL), ﬁbrinogen (FIB)
and D-dimer (D–D) by using automatic biochemical analyzer
and the contents of 6-keto prostaglandin F1a (6-keto-PGF1a),
thromboxane B2 (TXB2) were determined by ELISA kit.2.5. Statistical method
The data were input and analyzed by SPSS 21.0 software.
The analysis of measurement data between two groups was
carried out by t test. Differences were regarded as statistically
signiﬁcant when P < 0.05.
3. Results
3.1. General data
A total of 35 patients were included in Shuxuetong group
with 22 males and 13 females, age of (58.1 ± 7.2) years, body
mass index (BMI) of (23.89 ± 3.24) kg/m2. Among them, 19
cases were complicated with high blood pressure, 13 cases were
complicated with diabetes and 23 cases with smoking history. A
total of 39 patients were included in control group with 25 males
and 14 females, age of (57.4 ± 8.3) years, BMI of (23.61 ± 3.09)
kg/m2. Among them, 22 cases were complicated with high blood
pressure, 15 cases were complicated with diabetes and 24 cases
with smoking history. According to the statistic analysis, there
were no signiﬁcant differences in sex, age, BMI and number of
cases complicated with high blood pressure, diabetes and
smoking history in Shuxuetong group compared with control
group (Table 1).
3.2. Degree of nerve injury
One month after the treatment, the contents of serum NSE
[(7.96 ± 0.93) vs. (11.36 ± 1.84) ng/mL] and S100B [(0.95 ±
0.11) vs. (1.34 ± 0.18) ng/mL] in Shuxuetong group were
signiﬁcantly lower than those of control group. Three months
after the treatment, the contents of serum NSE [(5.47 ± 0.77) vs.
(8.93 ± 0.94) ng/mL] and S100B [(0.64 ± 0.07) vs. (1.03 ± 0.14)
ng/mL) in Shuxuetong group were signiﬁcantly lower than those
of control group. One month and three months after the treat-
ment, National Institutes of Health Stroke Scale, Traditional
Chinese Medicine syndrome score and the contents of serum
NSE and S100B in the two groups were statistically signiﬁcant
(P < 0.05) (Table 2).
3.3. Blood lipid metabolic indexes
One month after the treatment, the contents of serum TC
[(5.03 ± 0.67) vs. (5.44 ± 0.78) mmol/L], TG [(1.94 ± 0.22) vs.
(2.38 ± 0.31) mmol/L], LDL [(2.88 ± 0.35) vs. (3.24 ± 0.39)
mmol/L] and ox-LDL [(0.49 ± 0.07) vs. (0.61 ± 0.08) mg/L] in
Shuxuetong group were signiﬁcantly lower than those of control
group. The content of HDL [(1.58 ± 0.19) vs. (1.39 ± 0.14)
Table 2
Comparison on degree of nerve injury between the two groups. ng/mL.
Parameters Shuxuetong
group (n = 35)
Control
group (n = 39)
One month after treatment
NSE 7.96 ± 0.93* 11.36 ± 1.84
S100B 0.95 ± 0.11* 1.34 ± 0.18
Three months after treatment
NSE 5.47 ± 0.77* 8.93 ± 0.94
S100B 0.64 ± 0.07* 1.03 ± 0.14
Data are represented as mean ± SD. *: P < 0.05 compared with control
group.
Table 4
Comparison on coagulative function indexes of two groups.
Parameters Shuxuetong
group (n = 35)
Control
group (n = 39)
One month after treatment
6-keto-PGF1a (mg/L) 37.32 ± 5.24
* 28.34 ± 3.18
TXB2 (mg/L) 147.69 ± 19.36
* 203.53 ± 26.48
FIB (g/L) 3.68 ± 0.56* 4.92 ± 0.65
D–D (ng/L) 168.64 ± 21.48* 227.89 ± 29.14
Three months after treatment
6-keto-PGF1a (mg/L) 45.64 ± 6.37
* 32.14 ± 3.59
TXB2 (mg/L) 125.23 ± 18.42
* 184.53 ± 23.18
FIB (g/L) 3.03 ± 0.49* 4.52 ± 0.62
D–D (ng/L) 142.54 ± 17.53* 196.52 ± 23.54
Data are represented as mean ± SD. *: P < 0.05 compared with control
group.
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Three months after the treatment, the contents of serum TC
[(4.65 ± 0.61) vs. (5.17 ± 0.72) mmol/L], TG [(1.68 ± 0.19) vs.
(2.14 ± 0.28) mmol/L], LDL [(2.65 ± 0.29) vs. (3.05 ± 0.36)
mmol/L] and ox-LDL [(0.42 ± 0.05) vs. (0.59 ± 0.07) mg/L] in
Shuxuetong group were signiﬁcantly lower than those of control
group. The content of HDL [(1.73 ± 0.22) vs. (1.42 ± 0.18)
mmol/L] was signiﬁcantly higher than that of control group. One
month and three months after the treatment, the contents of
serum of TC, TG, LDL, ox-LDL and HDL were statistically
signiﬁcant (P < 0.05) (Table 3).
3.4. Coagulative function indexes
One month after the treatment, the content of serum 6-keto-
PGF1a [(37.32 ± 5.24) vs. (28.34 ± 3.18) mg/L] in Shuxuetong
group was signiﬁcantly higher than that of control group and the
contents of TXB2 [(147.69 ± 19.36) vs. (203.53 ± 26.48) mg/L],
FIB [(3.68 ± 0.56) vs. (4.92 ± 0.65) g/L] and D–D [(168.64 ±
21.48) vs. (227.89 ± 29.14) ng/L] were signiﬁcantly lower than
those of control group. Three months after the treatment, the
content of serum 6-keto-PGF1a [(45.64 ± 6.37) vs. (32.14 ± 3.59)
mg/L] in Shuxuetong group was signiﬁcantly higher than that of
control group and the contents of TXB2 [(125.23 ± 18.42) vs.
(184.53 ± 23.18) mg/L], FIB [(3.03 ± 0.49) vs. (4.52 ± 0.62) g/L]
and D–D [(142.54 ± 17.53) vs. (196.52 ± 23.54) ng/L] were
signiﬁcantly lower than those of control group. One month and
three months after the treatment, the contents of serum 6-keto-
PGF1a, TXB2, FIB and D–D were statistically signiﬁcant
(P < 0.05) (Table 4).Table 3
Comparison on blood lipid metabolic indexes of the two groups.
Parameters Shuxuetong
group (n = 35)
Control
group (n = 39)
One month after treatment
TC (mmol/L) 5.03 ± 0.67* 5.44 ± 0.78
TG (mmol/L) 1.94 ± 0.22* 2.38 ± 0.31
LDL (mmol/L) 2.88 ± 0.35* 3.24 ± 0.39
ox-LDL (mg/L) 0.49 ± 0.07* 0.61 ± 0.08
HDL (mmol/L) 1.58 ± 0.19* 1.39 ± 0.14
Three months after treatment
TC (mmol/L) 4.65 ± 0.61* 5.17 ± 0.72
TG (mmol/L) 1.68 ± 0.19* 2.14 ± 0.28
LDL (mmol/L) 2.65 ± 0.29* 3.05 ± 0.36
ox-LDL (mg/L) 0.42 ± 0.05* 0.59 ± 0.07
HDL (mmol/L) 1.73 ± 0.22* 1.42 ± 0.18
Data are represented as mean ± SD. *: P < 0.05 compared with control
group.4. Discussion
Aspirin and atorvastatin, respectively, are the western medi-
cine drugs with the effects of anticoagulation and lipid-lowering,
which are used in the secondary prevention treatment of ischemic
cerebral infarction[10–13]. However, for patients having had
ischemic cerebral infarction, it is not enough to effectively
correct the abnormal blood coagulation function and lipid
metabolism only by western medicine and the risk of re-
infarction becomes much higher. Shuxuetong injection is made
only fromChinesemedicines with main components of lumbricus
and leech which can promote blood circulation to remove blood
stasis. Modern pharmacological studies conﬁrmed that lumbricus
and leech can improve microcirculation, reduce blood viscosity
and also directly activate plasminogen and dissolve the ﬁbrous
protein[14,15]. In the process of ischemia and hypoxia injury, a
variety of biomarker molecules in the endochylema of neurons
and neurogliocyte will be released out of the cell, and then enter
the blood circulation through the blood brain barrier. S100B
protein is a kind of acidic calcium binding protein, which is
highly expressed in neurons promoting axonal growth and
neuronal differentiation[16,17]. NSE is a kind of enolization dimer
enzyme isozyme in neurons which can regulate the cellular
energy metabolism[18,19]. After the use of adjuvant therapy of
Shuxuetong injection in this study, through the detection of the
contents of the above two nerve damage markers to reﬂect the
degree of injury of nerve function, the results revealed that the
contents of serum S100B and NSE in Shuxuetong group were
signiﬁcantly lower than those of control group, which indicated
that Shuxuetong injection can reduce the nerve injury in patients
with ischemic cerebral infarction during rehabilitation.
Abnormal lipid metabolism is an important feature of patients
with ischemic cerebral infarction, which can increase the blood
viscosity and also can cause lipid deposition in endarterium and
form the atheromatous plaque. TG and cholesterol are important
lipid components in the body, and high levels of TG and choles-
terol in the serum are also considered to be a risk factor for cerebral
apoplexy. Cholesterol can be deposited in endarterium and
become an important component of atheromatous plaque, and TG
can accelerate the process of lipid deposition and promote the
formation of atheromatous plaque[20,21]. LDL can carry cholesterol
to the peripheral tissue, and get into the endarterium oxidized as
ox-LDL being able to further be swallowed by macrophages,
and then form foam cells[22,23]. HDL can transport cholesterol in
peripheral tissues to the liver, which has an inhibitory effect on
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metabolism is closely related to the occurrence of ischemic
cerebral infarction. And if the abnormal lipid metabolism in vivo
could not be effectively corrected, the risk of recurrence of
cerebral infarction will be increased. Lumbricus and leech in
Shuxuetong injection have pharmacological effects in regulating
blood lipid metabolism. Blood lipid metabolic indexes were
analyzed the results showed that the contents of serum TC, TG,
LDL and ox-LDL in Shuxuetong group were signiﬁcantly lower
than those of control group and the content of HDL was signiﬁ-
cantly higher than that of control group, which indicated that
adjuvant treatment with Shuxuetong injection can improve the
blood lipid metabolism in patients with ischemic cerebral infarc-
tion during rehabilitation.
In the course of ischemic cerebral infarction, the rupture of
the atherosclerotic plaque can cause local thrombosis, leading to
obvious abnormal blood coagulation function in the body.
Thromboxane A2 and prostaglandin F1a are important molecules
in regulating coagulation function and forming thrombus and
their metabolites are TXB2 and 6-keto-PGF1a. TXB2 and 6-keto-
PGF1a in the body are extremely stable. Through the detection
of the contents of the above two metabolites the function of
thromboxane A2 (TXA2) and PGF1a in vivo can be reﬂected. In
the course of forming arterial thrombus, TXA2 can increase the
expression of platelet membrane diabetes IIa/IIIas receptors and
promote platelet activation and aggregation. PGF1a can antag-
onize the function of TXA2, relax blood vessels and improve the
blood ﬂow perfusion[25,26]. FIB is a blood coagulation factor of
hepatic synthesis, directly involves in the process of blood
coagulation and can combine with platelet and aggregate the
platelet through the platelet membrane diabetes compound IIb-
IIIa. D–D is a frbrin monomer formed by ﬁbrinogen and
degradation product crosslinked by the activation factor X,
which can reﬂect hyperﬁbrinolysis and hypercoagulable state.
Coagulative function indexes were analyzed and the results
showed that the contents of serum TXB2, FIB and D–D in
Shuxuetong group were signiﬁcantly lower than those of control
group and the content of 6-keto-PGF1a was signiﬁcantly higher
than that of control group, which indicated that adjuvant treat-
ment with Shuxuetong injection can improve the coagulation
function in patients with ischemic cerebral infarction during
rehabilitation.
In summary, adjuvant treatment with Shuxuetong injection
can alleviate the injury of nerve function, improve the blood
lipid metabolism and coagulation function in patients with
ischemic cerebral infarction which is an effective drug for the
treatment of ischemic cerebral infarction.Conﬂict of interest statement
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